• A British pharmaceutical group in an exchange of strategic assets and the creation of a joint-venture with a Swiss pharmaceutical group.
    • A U.S. Fortune 500 group in its €150 million acquisition of a French leading group in security monitoring systems from financial sponsors.
    • A CAC 40 group in its acquisition of an international group specializing in the supply of industrial gases.
    • A sovereign state, as stakeholder in a CAC 40 company, on a £21 billion acquisition of a European industrial company.

    Life Sciences

    • Advanced Oncotherapy plc in connection with its strategic funding partnership and debt facility with Nerano Pharma.
    • A leading international brand name in pet care and wellness in the purchase of a pet care accessories, rawhides and veterinary medicines business in France, Italy and Spain.
    • A Sino-French venture capital fund on its investment in a French Contract Manufacturing Organization specialized in pharmaceutical development and the manufacture of high value-added sterile products.
    • The world's leading provider of non-invasive medical devices dedicated to the assessment of chronic liver diseases on a minority investment from a Sino-French venture capital fund and a US venture capital fund.
    • A leading pharmaceutical company in the implementation of several strategic assets transactions in France with a Swiss pharmaceutical company.
    • The shareholders of a French biotechnology company in the sale of 100% of the shares of the company to a Swiss pharmaceutical group.
    • A French investment company in the acquisition of a French biotechnology company through a LBO structure. 
    • A leading French pharmaceutical company in the acquisition of a group of French health services companies.
    • An American pharmaceutical and medical device group in the €170 million purchase of one of its major French suppliers.
    • One of the largest hospital management groups in the United States on its €320 million sale of one of France’s largest networks of clinics to private equity funds.
    • The shareholders of a French pharmaceutical group in its US$450 million sale to an American biopharmaceutical company.
    • The shareholders of the fourth largest independent French pharmaceutical group in its €195 million sale to an Indian pharmaceutical group.
    • Université Paris 2 Panthéon-Assas, DESS, Advanced Specialized Studies in Business and Tax Law, 1985
    • UCLA School of Law, LL.M., 1988
    • Paris
    • English
    • French
    • The Inside Counsel Revolution - Paris, France (April 20, 2016)